In previous studies, genetic engineering to incorporate a dominant negative Fas receptor in the CAR design, which disrupts the Fas-FasL interaction, has been shown to improve the anti-tumor activity and persistence of CAR T cells [42]. Here, FAS is linked to neoplasm.